Helix BioPharma (TSE:HBP) Shares Cross Below 50-Day Moving Average – Should You Sell?

Helix BioPharma Corp. (TSE:HBP)’s stock price passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of C$1.77 and traded as low as C$1.57. Helix BioPharma shares last traded at C$1.57, with a volume of 643 shares changing hands.

Helix BioPharma Price Performance

The stock has a fifty day moving average price of C$1.77 and a 200-day moving average price of C$1.99. The firm has a market capitalization of C$120.68 million, a PE ratio of -26.33 and a beta of 0.42. The company has a debt-to-equity ratio of 2.34, a quick ratio of 1.04 and a current ratio of 0.04.

Helix BioPharma (TSE:HBP) last announced its quarterly earnings results on Monday, March 16th. The biopharmaceutical company reported C($0.01) earnings per share (EPS) for the quarter. Sell-side analysts forecast that Helix BioPharma Corp. will post -0.11 EPS for the current fiscal year.

About Helix BioPharma

Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today’s front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery.